EP: 10.Multiple Myeloma Challenges and Treatment EvolutionThis is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP. Hinojosa explored treatment options beyond DRd (daratumumab, lenalidomide, dexamethasone), VRd (bortezomib, lenalidomide, dexamethasone), and KRd (carfilzomib...
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy. Along the disease course, the choice of specific therapy is affected by many variables inclu
Multiple Myeloma By Caroline Helwick/December 10, 2024 In Treatment of Transplant-Ineligible Myeloma, Addition of Isatuximab Improves Outcomes In the phase III IMROZ trial, the addition of the anti-CD38 monoclonal antibody isatuximab-irfc to bortezomib, lenalidomide, and dexamethasone (VRd) was mo...
“The diagnosis, workup, and treatment of myeloma have dramatically changed over the past 10 years. The therapeutic goal is to obtain deep remissions that translate into improved progression-free and overall survival. With combination therapy using immunomodulatory drugs, proteasome inhibitors, monoclonal...
The plasma cell neoplasm multiple myeloma (MM) is currently considered incurable. However, significant advances in treatment options over the past 20 years have led to unprecedented response rates to initial therapy as well as prolonged survival rates. Induction regimens have evolved from alkylator-...
Quadruplets Seen as Top Option in Transplant-Ineligible Multiple Myeloma Due to Efficacy Examining Safety: Daratumumab With VRd in Transplant-Ineligible Myeloma Insights From the AURIGA Trial in Multiple Myeloma Cilta-cel: Key Therapy for Unmet Needs in Myeloma Treatment?Related...
The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Darzalex Faspro plus VRd was approved by the FDA for induction and consolidation in newly diagnosed multiple myeloma eligible for ASCT. Subcutaneous Daratumumab Plus VRd Receives FDA Approval for Multiple Myeloma Daratumumab and hyaluronidase-fihj (Darzalex Faspro) was approved by the FDA in combinatio...
Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab By Jordyn Sava November 20th 2024 Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab By Targeted Oncology Staff November 19th 2024 Belantamab Mafodotin Triplet Boosts OS Over Daratumumab Regimen in Myelo...
Triplet therapy is the initial preferred treatment for myeloma, and various combinations are used around the world. A new combination, with the recently approved oral agent ixazomib (Ninlaro), can now be added to the options. It offers high responses and manageable toxicity at a reasonable cost,...